Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRENT trial of insulin glargine 300 U/mL versus insulin degludec 100 U/mL in insulin-naive adults with type 2 diabetes mellitus and renal impairment
2022-001485-35Phase 4Completed
- Sponsor
- Sanofi
- Start
- Jul 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing Insulin glargine 300 U/mL with Insulin degludec 100 U/mL (2 arms). Primary endpoint: Change in HbA1c from baseline to Week 24. Started Jul 2022; status: completed.
02
Drugs
insulin glargineinsulin degludec
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2022-001485-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001485-35.